Ad

IPCI – Intellipharmaceutics International Inc

Not Compliant

—X—

Intellipharmaceutics International Inc is not compliant with Shariah. The company’s financials fail all the five standards we check against.

$4,004,499

Market cap

-

Revenue Growth

-

Analysts' Rating

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Intellipharmaceutics International Inc. is a Canada-based pharmaceutical company. The Company is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses